Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 245,371 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 4,607 · Balance 245,371 F1: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 22:17 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 4,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000116 · wk-form4_1790979462.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,371 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:15 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 5,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000092 · wk-form4_1783026949.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,764 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 88,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000084 · wk-form4_1782160331.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,655 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:56 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 4,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001852075-26-000004 · wk-form4_1775163383.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,231 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:47 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 3,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001852075-26-000002 · wk-form4_1767739668.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,329 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:27 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001852075-25-000005 · wk-form4_1759523248.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,758 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000115 · wk-form4_1751571010.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,817 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 44,031 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001601830-25-000109 · wk-form4_1750713786.xml · derivative · entry 2 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,031 Underlying: Class A Common Stock · 44,031 shares Expires 2035-06-18 F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 22,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000109 · wk-form4_1750713786.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,893 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:37 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000055 · wk-form4_1743712590.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,877 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:02 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000006 · wk-form4_1736204565.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,132 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 22:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000173 · wk-form4_1728081013.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,225 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,843 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000098 · wk-form4_1720039188.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,996 F1 · kind: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 26,193 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001601830-24-000070 · wk-form4_1717625489.xml · derivative · entry 2 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,193 Underlying: Class A Common Stock · 26,193 shares Expires 2034-06-03 F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 3, 2025 or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 13,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000070 · wk-form4_1717625489.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,153 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 3, 2025 or the day prior to the Issuer's 2025 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:43 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000029 · wk-form4_1712180571.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,056 F1 · shares: Shares were issued pursuant to the Issuer's Outside Director Compensation Policy. F2 · balance_after: Includes a total of 32,373 shares received pursuant to a pro-rata distribution from Lux Ventures, of which the Reporting Person was a limited partner. The acquisition of such shares was exempt pursuant to Rule 16a-9 and was inadvertently excluded from the total amount of shares held on the Reporting Person's Forms 4 since July 12, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000002 · wk-form4_1704409883.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,216 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 23:44 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,141 | $9.00 | $181,269.00 |
DisclosureSEC source: 0001209191-23-059032 · doc4.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,823 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on June 21, 2023 Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 21:49 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052066 · doc4.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,964 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 22:08 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041654 · doc4.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,044 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:21 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 25,224 | $0.00 Strike: $8.92 | $0.00 |
DisclosureSEC source: 0001209191-23-038842 · doc4.xml · derivative · entry 2 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,224 Underlying: Class A Common Stock · 25,224 shares Expires 2033-06-16 F2 · shares: The shares subject to this option will vest and become exercisable on the earlier of June 16, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:21 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 12,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038842 · doc4.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,181 F1 · shares: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 16, 2024 or the day prior to the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 22:08 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023436 · doc4.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,561 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| April 03, 2023 Filed Apr 28, 2023 20:34 UTC Amendment | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026049 · doc4a.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,569 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. F2 · balance_after: Includes a total of 35,008 shares received pursuant to a pro-rata distribution from Lux Ventures, of which the Reporting Person was a limited partner. The acquisition of such shares was exempt pursuant to Rule 16a-9 and was inadvertently excluded from the total amount of shares held on the original Form 4 filing. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 21:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A Common Stock | 2,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-041947 · doc4.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,565 F1 · kind: Pro data distribution from Lux Ventures IV, L.P. and its affiliates, in a transaction which is exempt pursuant to Rule 16a-13 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 00:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (right to buy) · Derivative | 36,290 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001209191-22-037635 · doc4.xml · derivative · entry 2 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,290 Underlying: Class A Common Stock · 36,290 shares Expires 2032-06-14 Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 00:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 18,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037635 · doc4.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,145 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 14, 2023 or the day prior to the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A common stock | 3,599 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001585 · recursion_fm4dec72021.xml · nonDerivative · entry 1 Dar Zavain · CIK 0001852075 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,599 F1 · kind: Pro data distribution from Lux Ventures IV, L.P. and its affiliates, in a transaction which is exempt pursuant to Rule 16a-13 under the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.